Nazem Atassi, M.D.
Physician Investigator (Cl)
Neurology, Mass General Research Institute
Associate Professor of Neurology, Part-time
Harvard Medical School
Neurology, Massachusetts General Hospital
|MD Damascus University School of Medicine 2002|
|MD Damascus University 2001|
Dr. Nazem Atassi is Associate Director of the Neurological Clinical Research Institute at Massachusetts General Hospital, and Associate Professor of Neurology at Harvard Medical School. He has completed Neurology training at Boston University Medical Center and Fellowship in Neuromuscular Disorders and Clinical Trials at MGH.
Dr. Atassi received his Masters of Medical Science in 2010 from Harvard Medical School. He serves on the executive committee of the Northeast ALS Consortium (NEALS), and he is the founder and Co-Chair of the Upper Motor Neuron and the Imaging committees at NEALS.
Dr. Atassi received several awards including the MIT 100K Life Science Award from Massachusetts Institute of Technology, the Anne B. Young Translational Neuroscience Fellowship, and NIH K23 Career Development Award. He is completing Masters in Business Administration (MBA class 2019) at Sloan, Massachusetts Institute of Technology. He has hands-on industry experience in designing and running multicenter clinical trials through his work as a medical monitor for Pfizer and Fellow at Biogen.
Dr. Atassi is the Primary Investigator for several research projects focusing on Amyotrophic Lateral Sclerosis clinical trials, neuroimaging, and outcomes measures. His research is funded by the National Institute of Health, ALS Association, ALS Finding a Cure, ALS One Foundation, Muscular Dystrophy Association, and Harvard NeuroDiscovery Center.
Dr. Atassi directs the NCRI Imaging core which leverages a world-class research imaging infrastructure available at Mass General and apply these technologies to develop new ALS therapies. This Core is laser-focused on building novel imaging platforms that can measure the biological activity of experimental treatments in people living with ALS, leading to efficient clinical trial designs and accelerated pace of drug discovery.